Literature DB >> 28509134

Two cases of atypical hemolytic uremic syndrome (aHUS) and eosinophilic granulomatosis with polyangiitis (EGPA): a possible relationship.

Mercedes Cao1, Tamara Ferreiro2, Bruna N Leite2, Francisco Pita2, Luis Bolaños2, Francisco Valdés2, Angel Alonso2, Eduardo Vázquez3, Juan Mosquera3, María Trigás4, Santiago Rodríguez5.   

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by hemolysis, thrombocytopenia, and renal failure. It is related to genetic mutations of the alternative complement pathway and is difficult to differentiate from other prothrombotic microangiopathies. Eosinophilic granulomatosis with polyangiitis (EGPA) (Churg-Strauss syndrome, CSS) is a systemic ANCA-associated vasculitis and a hypereosinophilic disorder where eosinophils seem to induce cell apoptosis and necrosis and therefore, vasculitis. Here, we report the case of two CSS patients with a genetic complement disorder consistent with aHUS diagnosis. Both patients showed histologic features that supported the diagnosis of CSS, and a genetic complement study confirmed the suspected aHUS diagnosis. In the case where eculizumab was administered, the global response was excellent. There is very limited understanding of the genetics and epidemiology of both, atypical HUS and EGPA, but considering our two patients we suggest that an etiopathogenic link exists among patients diagnosed with both entities.

Entities:  

Keywords:  ANCA; Churg–Strauss syndrome; Complement; EGPA; Eculizumab; Eosinophilia; TMA; Vasculitis; aHUS

Year:  2017        PMID: 28509134      PMCID: PMC5438815          DOI: 10.1007/s13730-017-0251-8

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  33 in total

Review 1.  Atypical Hemolytic-Uremic Syndrome: A Clinical Review.

Authors:  Ali Nayer; Arif Asif
Journal:  Am J Ther       Date:  2016 Jan-Feb       Impact factor: 2.688

Review 2.  Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.

Authors:  Jacobien C Verhave; Jack F M Wetzels; Nicole C A J van de Kar
Journal:  Nephrol Dial Transplant       Date:  2014-09       Impact factor: 5.992

Review 3.  A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders.

Authors:  N Besbas; D Karpman; D Landau; C Loirat; W Proesmans; G Remuzzi; G Rizzoni; C M Taylor; N Van de Kar; L B Zimmerhackl
Journal:  Kidney Int       Date:  2006-06-14       Impact factor: 10.612

Review 4.  Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.

Authors:  Anna Richards; M Kathryn Liszewski; David Kavanagh; Celia J Fang; Elizabeth Moulton; Veronique Fremeaux-Bacchi; Giuseppe Remuzzi; Marina Noris; Timothy H J Goodship; John P Atkinson
Journal:  Mol Immunol       Date:  2006-08-01       Impact factor: 4.407

5.  [Hypereosinophilic syndrome developing after prednisolone therapy for autoimmune hemolytic anemia].

Authors:  Yuko Nakamura; Yukihiro Arai; Hisako Gunji; Honoka Arai; Fumihiko Nakamura; Tomoyuki Handa; Jiro Tadokoro; Kinuko Mitani
Journal:  Rinsho Ketsueki       Date:  2003-11

Review 6.  Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.

Authors:  Carla M Nester; Patrick D Brophy
Journal:  Curr Opin Pediatr       Date:  2013-04       Impact factor: 2.856

7.  Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy.

Authors:  Rosanna Coppo; Licia Peruzzi; Alessandro Amore; Silvana Martino; Luca Vergano; Inna Lastauka; Arrigo Schieppati; Marina Noris; Pier Angelo Tovo; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2014-08-31       Impact factor: 3.714

Review 8.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

9.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Authors:  C M Legendre; C Licht; P Muus; L A Greenbaum; S Babu; C Bedrosian; C Bingham; D J Cohen; Y Delmas; K Douglas; F Eitner; T Feldkamp; D Fouque; R R Furman; O Gaber; M Herthelius; M Hourmant; D Karpman; Y Lebranchu; C Mariat; J Menne; B Moulin; J Nürnberger; M Ogawa; G Remuzzi; T Richard; R Sberro-Soussan; B Severino; N S Sheerin; A Trivelli; L B Zimmerhackl; T Goodship; C Loirat
Journal:  N Engl J Med       Date:  2013-06-06       Impact factor: 91.245

Review 10.  Eosinophilic Granulomatosis With Polyangiitis With Thrombotic Microangiopathy: Is Simultaneous Systemic Lupus Erythematosus Associated With Clinical Manifestations?: A Case Report and Review of the Literature.

Authors:  Shoichi Fukui; Naoki Iwamoto; Sosuke Tsuji; Masataka Umeda; Ayako Nishino; Yoshikazu Nakashima; Takahisa Suzuki; Yoshiro Horai; Tomohiro Koga; Shin-Ya Kawashiri; Kunihiro Ichinose; Yasuko Hirai; Mami Tamai; Hideki Nakamura; Tomoki Origuchi; Naóe Kinoshita; Atsushi Kawakami
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

View more
  1 in total

Review 1.  Thrombotic microangiopathy in a patient with eosinophilic granulomatosis with polyangiitis: case-based review.

Authors:  Jon Badiola; Nuria Navarrete-Navarrete; José Mario Sabio
Journal:  Rheumatol Int       Date:  2018-12-15       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.